Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders

Neurogastroenterology and Motility

Volumn 27, Issue 11, 2015, Pages 1580-1586

  Paula, H ^a   Grover, M ^b   Halder, S L ^c   Locke, G R ^b   Schleck, C D ^b   Zinsmeister, A R ^b   Talley, Nicholas J ^b,d  

^a Medizinisch Diagnostische Laboratorium West OG   (Austria)

^b MAYO CLINIC   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Antibiotics; Functional GI disorders; Irritable bowel syndrome; Non enteric infections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DYSPEPSIA; FEMALE; HUMAN; INFECTION; INTESTINE INFECTION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SELF REPORT; AGE DISTRIBUTION; AGED; CASE CONTROL STUDY; GASTROINTESTINAL DISEASES; MIDDLE AGED; ODDS RATIO; SEX RATIO; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFECTION; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEX DISTRIBUTION; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84945490230     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12655     Document Type: Article

References (39)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-90.
2. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68.
3. Gwee KA, Chua AS. Functional dyspepsia and irritable bowel syndrome, are they different entities and does it matter? World J Gastroenterol 2006; 12: 2708-12.
4. Parry S, Forgacs I. Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005; 17: 5-9.
5. Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008; 20(Suppl. 1): 121-9.
6. Neil K, Hebden H, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-82.
7. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-6.
8. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318: 565-6.
9. Parry SD, Stansfield R, Jelley D, Gregory W, Phillips E, Barton JR, Welfare MR. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98: 1970-5.
10. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
11. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-88.
12. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010; 59: 605-11.
13. Grover M, Camilleri M, Smith K, Linden DR, Farrugia G. On the fiftieth anniversary: postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterol Motil 2014; 26: 156-67.
14. Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51: 1026-32.
15. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20: 381-6.
16. Rhodes DY, Wallace M. Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2006; 8: 327-32.
17. Mearin F, Perez-Oliveras M, Perello A, Vinyet J, Ibanez A, Coderch J, Perona M. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98-104.
18. Dizdar V, Spiller R, Singh G, Hanevik K, Gilja OH, El-Salhy M, Hausken T. Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2010; 31: 883-91.
19. Porter CK, Faix DJ, Shiau D, Espiritu J, Espinosa BJ, Riddle MS. Postinfectious gastrointestinal disorders following Norovirus outbreaks. Clin Infect Dis 2012; 55: 915-22.
20. Maxwell PR, Rink E, Kumar D, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002; 97: 104-8.
21. Quigley EM. Germs, gas and the gut; the evolving role of the enteric flora in IBS. Am J Gastroenterol 2006; 101: 334-5.
22. Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995; 142: 76-83.
23. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991; 101: 927-34.
24. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671-4.
25. Rey E, Locke GR 3rd, Jung HK, Malhotra A, Choung RS, Beebe TJ, Schleck CD, Zinsmeister AR et al. Measurement of abdominal symptoms by validated questionnaire: a 3-month recall timeframe as recommended by Rome III is not superior to a 1-year recall timeframe. Aliment Pharmacol Ther 2010; 31: 1237-47.
26. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): II37-42.
27. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II43-7.
28. Choung R, Locke GR III, Schleck C, Ziegenfuss J, Beebe T, Zinsmeister A, Talley N. A low response rate does not necessarily indicate non-response bias in gastroenterology survey research: a population-based study. J Public Health 2013; 21: 87-95.
29. Center for Disease Control and Prevention. Estimating Foodborne Illness: An Overview, 2011. Available at: http://www.cdc.gov/foodborneburden/estimates-overview.html
30. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5: 457-60.
31. Zanini B, Ricci C, Bandera F, Caselani F, Magni A, Laronga AM, Lanzini A. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol 2012; 107: 891-9.
32. McKeown ES, Parry SD, Stansfield R, Barton JR, Welfare MR. Postinfectious irritable bowel syndrome may occur after non-gastrointestinal and intestinal infection. Neurogastroenterol Motil 2006; 18: 839-43.
33. Uusijarvi A, Bergstrom A, Simren M, Ludvigsson JF, Kull I, Wickman M, Alm J, Olen O. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain-a Swedish birth cohort study. Neurogastroenterol Motil 2014; 26: 841-50.
34. Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737-45.
35. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, Malinen E, Apajalahti J et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
36. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63.
37. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33.
38. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-49; quiz 1050.
39. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-3.